On Thursday, November 19, 2026, U.S. equity markets experienced significant weakness as the S&P 500 fell 2.0% and the Nasdaq Composite declined 2.3%, driven primarily by continued selling pressure in artificial-intelligence stocks despite Anthropic's record-breaking initial public offering [1][2][3][4]. The broad-based selloff affected multiple sectors, with healthcare technology and consumer discretionary stocks particularly hard hit.
Healthcare technology stocks bore the brunt of the decline. Veeva Systems (VEEV) fell 5.2%, outpacing the broader market decline and falling harder than the median 3.1% drop among six other healthcare technology companies worth $2 billion or more [1]. Zoetis (ZTS), a pharmaceutical company, declined 5.6% despite announcing that the U.S. Department of Agriculture had licensed a new vaccine for chickens called Poulvac Procerta [2]. The Health Care Select Sector SPDR Fund (XLV) fell 2.0%, in line with the S&P 500 [1]. In consumer discretionary, SharkNinja (SN) fell 5.8% on the same day the company introduced the RazorVac cordless hand vacuum priced from $129.99, even though the cleaning category represented the slowest-growing of the company's four categories with only 4.1% growth [3].
Semiconductor stocks experienced particularly severe declines. Taiwan Semiconductor Manufacturing (TSMC) fell more than 11.7% in four trading days from the prior Friday's close, marking the worst week since the one ending March 20, 2020 [4]. Taiwan's broader market, represented by the iShares MSCI Taiwan ETF (EWT), fell 13.8% from November 13 to November 19, with only three weeks since June 2000 being worse for that fund [4]. Historical analysis shows that in 15 of TSMC's 16 past episodes of similar magnitude declines, the stock continued sliding, with the lowest close in the year after each bad week being a median 26.3% below that week's close [4].
Notably, Insmed (INSM) bucked the broader market trend, rising 20.6% on reports that Sanofi is considering an acquisition of the biotech company [5]. Insmed reported Q3 2026 revenue of $524 million, up 268.4% year-over-year, with its main drug BRINSUPRI generating $400.1 million that quarter and the company raising its full-year 2026 sales forecast for BRINSUPRI to $1.35-$1.4 billion [5]. The company's operating loss narrowed to $81.8 million in Q3 2026 from $261 million a year earlier, with management expecting cash flow to turn positive in 2027 [5].
Other sectors showed mixed performance. Nucor (NUE) has delivered strong returns of 68.6% over the past twelve months compared with 9.7% for the S&P 500, though its raw materials segment saw earnings decline to $105 million in Q3 2026 from $146 million in Q2 2026 due to lower pricing and shipments [7]. AT&T (T) has underperformed the market, losing 10.6% over the past year with dividends included while the S&P 500 gained 9.7%, though the company is expanding fiber and wireless bundled services with 416,000 net fiber customer additions in Q3 2026 [6]. United Parcel Service (UPS) has significantly underperformed, falling 48.8% on price alone over five years while the S&P 500 rose 54.4%, though dividends added 14.6 percentage points to UPS's total return [8].
CONCLUSION
The November 19, 2026 market selloff was driven by persistent weakness in artificial-intelligence stocks and affected multiple sectors, with healthcare technology and semiconductors experiencing the steepest declines. While most stocks fell in line with or exceeded broader market weakness, Insmed's 20.6% surge on acquisition speculation and Nucor's strong year-to-date performance of 52.9% demonstrate that sector rotation and company-specific catalysts continue to create divergence within the broader market downturn. Investors should monitor upcoming earnings reports and forward guidance, particularly from Veeva (December 2026), Zoetis (February 2027), and Nucor (January 2027), to assess whether current valuations and growth expectations remain justified.